Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen in prostatic cancer.

J C Baron1, C Peyret, M Leroy

  • 1Department of Urology, Hôpital Saint Louis, Paris, France.

American Journal of Clinical Oncology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does frontal cortex hypometabolism in progressive supranuclear palsy result from subcortical dysfunction?

European journal of neurology·2013
Same author

Clues about the functional neuroanatomy of verbal working memory: a study of resting brain glucose metabolism in Parkinson's disease.

European journal of neurology·2013
Same author

Pharmacological therapies in post stroke recovery: recommendations for future clinical trials.

Journal of neurology·2013
Same author

Ultraviolet laser-induced autofluorescence distinction between malignant and normal urothelial cells and tissues.

Journal of biomedical optics·2012
Same author

A microPET study of the regional distribution of [11C]-PK11195 binding following temporary focal cerebral ischemia in the rat. Correlation with post mortem mapping of microglia activation.

NeuroImage·2011
Same author

Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat.

NeuroImage·2009
Same journal

Care Patterns and Gastric Cancer-Related Outcomes in Patients With Pathogenic/Likely Pathogenic Germline CDH1 Variants: A 14-Year Single-Center Analysis.

American journal of clinical oncology·2026
Same journal

Upper Extremity Lymphedema​​​: Performance of a Risk Prediction Model in Women Undergoing Surgery for Breast Cancer.

American journal of clinical oncology·2026
Same journal

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO).

American journal of clinical oncology·2026
Same journal

Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach.

American journal of clinical oncology·2026
Same journal

Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States.

American journal of clinical oncology·2026
Same journal

Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery: A Real-World Cohort Study.

American journal of clinical oncology·2026
See all related articles

Prostate-specific antigen (PSA) is not a definitive marker for prostate cancer. Elevated serum PSA levels warrant medical attention, as they can indicate either prostate cancer or benign prostatic hypertrophy (BPH).

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Prostate-specific antigen (PSA) is a biomarker used in prostate cancer management.
  • Distinguishing between prostate cancer and benign prostatic hypertrophy (BPH) can be challenging based on PSA levels alone.

Purpose of the Study:

  • To evaluate the diagnostic value of serum PSA measurements in differentiating prostate cancer from BPH.
  • To determine the specificity of PSA as a marker for prostatic malignancy.

Main Methods:

  • Serum PSA levels were measured in 600 patients.
  • Included 75 treatment-naïve prostate cancer patients and patients with BPH.
  • Statistical analysis of PSA levels between groups.

Main Results:

Related Experiment Videos

  • Significant differences in mean PSA levels were observed between the overall BPH and cancer groups.
  • Less pronounced differences were noted between BPH and localized prostate cancer.
  • PSA levels above 50 ng/ml were not found in BPH patients, but lower levels were common in both conditions.

Conclusions:

  • Serum PSA is not a specific diagnostic marker for prostate cancer.
  • Elevated PSA levels, even below 50 ng/ml, necessitate further investigation for potential prostate cancer.
  • PSA serves as an important indicator for further clinical evaluation rather than a standalone diagnostic tool.